Would OncotypeDx impact your decision to provide adjuvant chemotherapy for node-negative HR+ breast cancer with dermis or chest wall involvement?  

While I'm tempted to use Oncotype or other genomic assays to omit chemotherapy as much as possible (and TBH, Oncotype may be more of a prognostic than predictive assay except at the very upper range - see Mitch Dowsett's examination of these assays, Buus et al., PMID 33108242), the prospective trial...